Neoadjuvant chemotherapy is commonly used in locally advanced breast cancer and selected patients with human epidermal growth factor receptor 2 (HER2) overexpressed and triple negative breast cancer [1]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.